ArticleBMC infectious diseases2026
Detection and clinical analysis of human coronavirus infection in pediatric patients with acute respiratory tract infection in the Xiamen Area, China, 2022-2024.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThis study aimed to investigate the prevalence of human coronavirus (HCoV) infection among pediatric patients with acute respiratory tract infection (ARTI) and to analyze the associated clinical features.
methodsA total of 15,281 pediatric patients diagnosed with ARTI admitted to Xiamen Children’s Hospital between January 2022 and June 2024 were included in this study. Clinical symptoms and signs in HCoV-positive patients were analyzed and compared with those of patients with respiratory syncytial virus (RSV) infection during the same period.
resultsHCoV was detected in 147 of 15,281 patients, corresponding to a detection rate of 0.93%. Annual detection rates were 0.87% (54/6,230) in 2022, 0.82% (53/6,439) in 2023, and 1.53% (40/2,612) in 2024. Detection rates were highest in autumn and winter, peaking in November (1.89%). Of the 147 cases, 80 involved HCoV mono-infection, while 67 were co-infected with other respiratory viruses. The most common HCoV-associated clinical manifestations were cough, fever, and wheezing. The incidence of wheezing was higher in the RSV group compared to the HCoV group (p < 0.05). No statistically significant differences were observed between the two groups regarding other symptoms, complications, or the proportion of cases requiring mechanical ventilation (p > 0.05).
conclusionsThe HCoV detection rate among pediatric patients with ARTI in Xiamen between January 2022 and June 2024 was 0.96%. The clinical manifestations and severity of HCoV-associated ARTI were comparable to those of RSV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.